Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-04-26
2011-04-26
Bristol, Lynn (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S085600, C424S155100
Reexamination Certificate
active
07931897
ABSTRACT:
An inducing agent or enhancing agent, for the expression of HM1.24 antigen in hematopoietic tumor cells, comprising interferon α, interferon γ, or the IRF-2 protein as an active ingredient, as well as an anti-tumor agent for hematopoietic tumors which comprises a combination of said inducing agent or enhancing agent and an antibody against HM1.24.
REFERENCES:
patent: 4401756 (1983-08-01), Gillis
patent: 5328989 (1994-07-01), Vellekamp et al.
patent: 5756318 (1998-05-01), Kosuna
patent: 5830463 (1998-11-01), Duke et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6258352 (2001-07-01), Shimonaka
patent: 6503510 (2003-01-01), Koishihara et al.
patent: 2002/0037288 (2002-03-01), Koishihara et al.
patent: 2003/0175281 (2003-09-01), Kosaka et al.
patent: 2006/0193828 (2006-08-01), Kosaka et al.
patent: 0 125 023 (1984-11-01), None
patent: 0 239-400 (1987-09-01), None
patent: 0 256 714 (1988-02-01), None
patent: 0 733 643 (1996-09-01), None
patent: 0 770 628 (1997-05-01), None
patent: 0 960 936 (1999-12-01), None
patent: 0 997 152 (2000-05-01), None
patent: 0 997 152 (2000-05-01), None
patent: 1-59878 (1989-04-01), None
patent: 7-196694 (1995-01-01), None
patent: 7-236475 (1995-09-01), None
patent: WO-83/04313 (1983-12-01), None
patent: WO-92/01047 (1992-01-01), None
patent: WO-92/03918 (1992-03-01), None
patent: WO-92/20791 (1992-11-01), None
patent: WO-93/06213 (1993-04-01), None
patent: WO-93/11236 (1993-06-01), None
patent: WO-93/12227 (1993-06-01), None
patent: WO-93/19172 (1993-09-01), None
patent: WO-94/02602 (1994-02-01), None
patent: 94/06818 (1994-03-01), None
patent: WO 94/06818 (1994-03-01), None
patent: WO-94/11523 (1994-05-01), None
patent: WO-94/25585 (1994-11-01), None
patent: WO-95/01438 (1995-01-01), None
patent: WO-95/15388 (1995-06-01), None
patent: WO-96/02576 (1996-02-01), None
patent: WO-96/04925 (1996-02-01), None
patent: WO-96/30394 (1996-03-01), None
patent: WO-96/33735 (1996-10-01), None
patent: WO-96/34096 (1996-10-01), None
patent: WO-98/14580 (1998-04-01), None
patent: WO-98/35698 (1998-08-01), None
patent: 99/18997 (1999-04-01), None
patent: WO-99/18997 (1999-04-01), None
patent: 01/13940 (2001-03-01), None
patent: 01/97844 (2001-12-01), None
Ozaki et al. (Blood 94(10) Suppl. 1:549a (1999).
Search output from ATCC website for anti-HM1.24 monoclonal antibody/hybridoma deposit (pp. 1-2).
Fundamental Immunology 242 (William E. Paul, M.D. ed., 3d ed. 1993).
Sequence search alignment for SEQ ID No. 2 (pp. 1-2).
Ohtomo et al. (Biochem. Biophys. Res. Comm. 258:583-591 (1999).
Blasius et al. (J. Immunol. 177:3260-3265 (2006)).
ATCC data sheet for ARH-77 cell line.
Stedman's On-line Medical Dictionary, 27th Ed., “myeloma” pp. 1-3 (Mar. 9, 2009).
Voskoglou-Nomikos (Clin. Can. Res. 9:4227-4239 (2003)).
Dennis (Nature 442:739-741 (2006)).
Cespdes et al. (Clin. Transl. Oncol. 8(5):318-329 (2006)).
Talmadge et al. (Am. J. Pathol 170(3):793-804 (2007)).
Fujimori et al. (J. Nuc. Med. 31:1191-1198 (1990)).
Beckman et al. (Can. 109:170-179 (2007)).
Thurber et al. (Adv. Drug Deliv. Rev. 60:1421-1434 (2008)).
Rudnick et al. (Can. Biotherp. & Radiopharm. 24: 155-162 (2009)).
S. Ozaki et al., “Humanized Anti-HM1.24 Antibody Mediates Myeloma Cell Cytotoxicity that is Enhanced by Cytokine Stimulation of Effector Cells,”Blood, vol. 93, No. 11, pp. 3922-3930, 1999.
S. Koenig et al., “Cloning of an Interferon Regulatory Factor 2 Isoform with Different Regulatory Ability,”Nucleic Acids Research, vol. 28, No. 21, pp. 4219-4224, 2000.
T. Jesse et al., “Interferon Regulatory Factor-2 is a Transcriptional Activator in Muscle where it Regulates Expression of Vascular Cell Adhesion Molecule-1,”The Journal of Cell Biology, vol. 140, No. 5, pp. 1265-1276, 1998.
Shuji Ozaki et al. (1999) “Interferon-alpha and gamma enhance the HM1.24 Expression on Myeloma Cells Through the STAT-signaling Pathway,” Blood 94(10), pp. 549a.
Supplementary Partial Search Report dated Oct. 26, 2005, directed to a corresponding foreign application.
Goto et al. (Sep. 15, 1994). “A Novel Membrane Antigen Selectively Expressed on Terminally Differentiated Human B Cells”Blood. 84(6): 1922-1930.
Kayo Inaba et al. “Contrasting Effect of α/β- and γ-Interferons On Expression Of Macrophage Ia Antigens,” Department of Zoology, Faculty of Science, and the Institute for Virus Research, Kyoto University, Kyoto, Japan, vol. 163, Apr. 1986, pp. 1030-1035.
Michele Maio et al. “Modulation by Interferons of HLA Antigen, High-Molecular-Weight Melanoma-associated Antigen, and Intercellular Adhesion Molecule 1 Expression by Cultured Melanoma Cells with Different Metastatic Potential,” Cancer Research 49, Jun. 1, 1989, pp. 2980-2987.
Susan E. Dovhey et al. “Loss of Interferon-γ Inducibility of TAP1 and LMP2 in a Renal Cell Carcinoma Cell Line,” Cancer Research 60, Oct. 15, 2000, pp. 5789-5796.
Arora et al. (1998) Differential Myeloma Cell Responsiveness to Interferon-Alpha Correlates with Differential Induction of p19INK4d and Cyclin D2 Expression JBC 273(19), pp. 11799-11805.
Australian Office Action dated May 18, 2004.
Australian Office Action mailed Apr. 1, 2005, directed to counterpart foreign application.
Birnbaum et al., “Phosphorylation of the Oncogenic Transcription Factor Interferon Regulatory Factor 2 (IRF2) In Vitro and In Vivo”, Journal of Cellular Biochemistry 66 (1997) pp. 175-183.
Bungard et al., (1998) “The Combination of IL-2 and IFN Alpha Effectively Augments the Antibody-Dependent Cellular Cytotoxicity of Monoclonal Antibodies 17-1A and BR 55-2 Against the Colorectal Carcinoma Cell Line HT29,” Cancer Immun Immunothe 46, pp. 213-220.
Cha et al, “Human Interferon Regulatory Factor 2 Gene,”The Journal of Biological Chemistry, vol. 269, No. 7, Feb. 18, 1994, pp. 5279-5287.
European Office Action mailed Oct. 21, 2005 directed to EP Application No. 00953561.8.
Ishikawa et al. “Molecular Cloning and Chromosomal Mapping of a Bone Marrow Stromal Cell Surface Gene, BST2, That May Be Involved in Pre-B-Cell Growth” A Stromal Cell Molecule Involved in Pre-B-Cell Growth, Cenomics 26, pp. 527-534, 1996.
Kosaka et al. “Advances in Understanding Biology and Pathogenesis of Multiple Myeloma” Japanese Clinical vol. 53, No. 3, Mar. 1995, pp. 627-635.
Langer et al. “Interferon Receptors” Immunology Today, vol. 9, No. 12, 1988, pp. 393-400.
Lengyel “Tumor-suppressor Genes: News About the Interferon Connection” Proc. Natl. Acad. Sci. USA, vol. 90, pp. 5893-5895, Jul. 1993.
Ludwig et al. “Current Controversies in Cancer—Should Alpha-interferon be Included as Standard Treatment in Multiple Myeloma?” European Journal of Cancer, vol. 34, No. 11, pp. 12-24, 1998.
Mellstedt et al. (Oct. 1991) “Treatment of Multiple Myeloma with Interferon Alpha: the Scandinavian Experience,” Br J Haernatol vol. 79, Supp 1, pp. 21-25.
Office Action Report from European Patent Office dated Apr. 6, 2004.
Ozaki et al. (1997) “Immunotherapy of Multiple Myeloma with a Monoclonal Antibody Directed Against a Plasma Cell-Specific Antigen, HM1.24”Blood90(8), pp. 3179-3186.
Pestka et al. “Interferons and Their Actions” Am. Rev. Biochem. vol. 56, 1987, pp. 727-777.
Platanias, Leonidas C., et al. “Signaling Pathways Activated by Interferons,” Experimental Hematology 27 (1999) pp. 1583-1592.
The Merck Index(12thEd.) Merck & Co., Inc., 1996, pp. 856-857, entries 5016 and 5018.
US Office Action directed U.S. Appl. No. 10/069,290 mailed Oct. 6, 2004 (7 pages).
US Office Action directed to U.S. Appl. No. 10/069,290 mailed Feb. 4, 2005 (9 pages).
US Office Action directed to U.S. Appl. No. 10/069,290 mailed Oct. 14, 2005 (7 pages).
US Office Action directed to U.S. Appl. No. 11/402,927 mailed Apr. 29, 2008 (14 pages).
US Office Action directed to U.S. Appl. No. 11/402,927 mailed Feb. 17, 2009 (8 pages).
Verharr, M., et al., “
Kosaka Masaaki
Ozaki Shuji
Wakahara Yuji
Bristol Lynn
Chugai Seiyaku Kabushiki Kaisha
Morrison & Foerster / LLP
LandOfFree
Therapeutic agent for hematopoietic tumors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agent for hematopoietic tumors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agent for hematopoietic tumors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2627952